Treatment of short bowel syndrome patients with colon-in-continuity
Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
1. A method for treating a patient with short bowel syndrome with colon-in-continuity with remnant small intestine, the method comprising:
administering to the patient an amount of a GLP-2 receptor agonist that is effective to reduce intestinal wet weight excretion in the patient,
wherein the GLP-2 receptor agonist is selected from the group consisting of a GLP-2 peptide, a GLP-2 analog, a derivatized GLP-2 peptide, and a derivatized GLP-2 analog.
2. The method of claim 1 , wherein the reduction in intestinal wet weight excretion is a decrease in fecal wet weight excretion.
3. The method of claim 1 , wherein the patient has at least 25% colon-in-continuity with remnant small intestine.
4. The method of claim 1 , wherein the patient has at least 50% colon-in-continuity with remnant small intestine.
5. The method of claim 1 , wherein the patient has at least 75% colon-in-continuity with remnant small intestine.
6. The method of claim 1 , wherein the patient has colon sufficient to produce endogenous GLP-2 plasma levels of at least 5 pmol/L in the fed state.
7. The method of claim 1 , wherein the patient has colon sufficient to produce endogenous GLP-2 plasma levels of at least 10 pmol/L in the fed state.
8. The method of claim 1 , wherein the remnant small intestine has a length of at least 25 cm.
9. The method of claim 1 , wherein the remnant small intestine has a length of at least 50 cm.
10. The method of claim 1 , wherein the GLP-2 receptor agonist is administered at least daily.
11. The method of claim 1 , wherein the GLP-2 receptor agonist is administered at least twice daily.
12. The method of claim 1 , wherein the GLP-2 receptor agonist is administered over a period of at least 21 days.
13. The method of claim 1 , wherein the GLP-2 receptor agonist is administered via injection or infusion.
14. The method of claim 13 , wherein injection is selected from the group consisting of subcutaneous injection, intramuscular injection, intravenous injection, and depot injection.
15. The method of claim 1 , wherein the GLP-2 receptor agonist is a mammalian GLP-2 peptide.
16. The method of claim 15 , wherein the mammalian GLP-2 is human GLP-2 peptide.
17. The method of claim 1 , wherein the GLP-2 receptor agonist is a GLP-2 analog.
18. The method of claim 17 , wherein the GLP-2 analog is a human GLP-2analog.
19. The method of claim 1 , wherein the GLP-2 receptor agonist is [Gly2]hGLP-2.
20. The method of claim 1 , wherein the patient's short bowel syndrome is secondary to one or more conditions selected from the group consisting of Crohn's disease, vascular ischemic disease, mesenteric infarction, malrotation, volvulous, trauma, injury, a congenital anomaly, a stricture, and any combinations thereof.
21. The method of claim 1 , wherein the patient has had a small bowel resection prior to the treatment.
22. The method of claim 1 , wherein the patient is dependent on parenteral support.
23. The method of claim 1 , wherein the GLP-2 receptor agonist is [Gly2]hGLP-2, wherein the patient has at least 25% colon-in-continuity with remnant small intestine, wherein the patient has colon sufficient to produce endogenous GLP-2 plasma levels of at least 5 pmol/L in the fed state and wherein the amount of the GLP-2 receptor agonist is at least 0.10 mg/kg/d.